tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Oncolytics Biotech to Delist from TSX, Focus on Nasdaq

Story Highlights
Oncolytics Biotech to Delist from TSX, Focus on Nasdaq

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Oncolytics Biotech ( (TSE:ONC) ) has provided an update.

On August 8, 2025, Oncolytics Biotech announced its decision to voluntarily delist its common shares from the Toronto Stock Exchange, effective August 22, 2025. This strategic move is aimed at focusing on its Nasdaq listing, where the shares will continue to trade under the symbol ‘ONCY’. The decision aligns with the company’s U.S. focus and shareholder base, and it is considering re-domiciling to the U.S. in the future. The delisting is not expected to impact Canadian shareholders, who can continue trading through U.S.-registered broker-dealer affiliates.

The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.

Spark’s Take on TSE:ONC Stock

According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.

Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.

To see Spark’s full report on TSE:ONC stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for the treatment of metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact.

Average Trading Volume: 255,403

Technical Sentiment Signal: Hold

Current Market Cap: C$125.6M

For an in-depth examination of ONC stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1